Skip to main content

Ascendis Pharma A/S (ASND)

NASDAQ: ASND · IEX Real-Time Price · USD
168.30 10.58 (6.70%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap8.96B
Revenue (ttm)6.02M
Net Income (ttm)-545.09M
Shares Out56.84M
EPS (ttm)-10.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume249,509
Open158.48
Previous Close157.72
Day's Range156.98 - 169.84
52-Week Range109.36 - 183.98
Beta0.80
AnalystsStrong Buy
Price Target195.76 (+16.3%)
Est. Earnings DateNov 10, 2021

About ASND

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorpo...

IndustryBiotechnology
IPO DateJan 28, 2015
CEOJan Moeller Mikkelsen
Employees482
Stock ExchangeNASDAQ
Ticker SymbolASND
Full Company Profile

Financial Performance

In 2020, ASND's revenue was 6.95 million, a decrease of -48.01% compared to the previous year's 13.38 million. Losses were -418.96 million, 92.2% more than in 2019.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 11 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price forecast is 195.76, which is an increase of 16.32% from the latest price.

Price Target
$195.76
(16.32% upside)
Analyst Consensus: Strong Buy

News

Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Cont...

– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –

1 day ago - GlobeNewsWire

Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study

Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.

2 weeks ago - Zacks Investment Research

Ascendis Pharma A/S Announces Upcoming Investor Presentations

COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...

2 weeks ago - GlobeNewsWire

Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program

– TransCon IL-2 β/γ  is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation ...

2 weeks ago - GlobeNewsWire

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

COPENHAGEN, Denmark, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...

3 weeks ago - GlobeNewsWire

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

COPENHAGEN, Denmark, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treat...

3 weeks ago - GlobeNewsWire

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – ...

Other symbols:CARAJAZZSESNSNY
3 weeks ago - Benzinga

Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa

Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.

3 weeks ago - Zacks Investment Research

Why Shares of Ascendis Soared This Week

The pharmaceutical company saw its shares jump more than $26.

4 weeks ago - The Motley Fool

Here's Why Ascendis Pharma Shares Are Surging Higher Today

Approval of the company's weekly growth hormone is making investors smile today.

4 weeks ago - The Motley Fool

See Why Ascendis Pharma Stock Is Shining On Thursday

The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASDAQ: ASND) long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the somatropin prodrug has been approved in kids ag...

4 weeks ago - Benzinga

These 2 Stocks Soared Double Digits After Hours

Find out where the big winners were late Wednesday.

Other symbols:WSM
4 weeks ago - The Motley Fool

Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results

– Announced U.S. Food and Drug Administration Approval of SKYTROFA ® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency –

4 weeks ago - GlobeNewsWire

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the F...

- SKYTROFA, the first FDA approved treatment utilizing TransCon™ technology, is a long-acting prodrug of somatropin that releases the same somatropin used in daily therapies –

4 weeks ago - GlobeNewsWire

Is a Surprise Coming for Ascendis Pharma (ASND) This Earnings Season?

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months

All it will take is an FDA approval and a partial repeat of history.

Other symbols:BMRN
1 month ago - The Motley Fool

Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25

COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates th...

1 month ago - GlobeNewsWire

Ascendis Pharma A/S Announces Upcoming Investor Presentations in August

COPENHAGEN, Denmark, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create new product candidate...

1 month ago - GlobeNewsWire

Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension

Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.

3 months ago - Zacks Investment Research

Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months

The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S's (NASDAQ: ASND) TransCon hGH (lonapegsomatropin) for the treatment of pediatric growth hormone deficiency. Ci...

3 months ago - Benzinga

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapeg...

Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021 Prescription Drug User Fee Act (PDUFA) goal date extended by three months...

3 months ago - GlobeNewsWire

The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial

1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China...

3 months ago - PRNewsWire

What 5 Analyst Ratings Have To Say About Ascendis Pharma

Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1 Somewhat Bullish 0 2 0 1 Indifferent ...

3 months ago - Benzinga

Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of W...

Online event to include a live reading by Children's Author, Ariana Feiner, whose short film documentary, A Story of Courage, has won 24 international awards Online event to include a live reading by Ch...

3 months ago - GlobeNewsWire

Ascendis Pharma A/S Reports First Quarter 2021 Financial Results

– Pre-launch activities continue in preparation for a potential FDA approval of TransCon™ hGH (lonapegsomatropin) for pediatric growth hormone deficiency; PDUFA date of June 25, 2021 –

3 months ago - GlobeNewsWire